Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?
Author:
Corresponding Author:

Affiliation:

1Department of Ophthalmology, School of Medicine, Baskent University, Konya 42080 Turkey;
2Department of Ophthalmology, School of Medicine, Izmir University, Izmir 35530, Turkey;
3Department of Ophthalmology, Bayındır Hospital, Ankara 06520 Turkey;
4Department of Ophthalmology Selçuk University Faculty of Medicine, Konya 42050 Turkey

Clc Number:

Fund Project:


Conflicts of Interest: Karalezli A, None; Kucukerdonmez C, None; Akova YA, None; Koktekir BE, None.

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    AIM:To assess the effect of topical bevacizumab use on postoperative pterygium recurrence in eyes who underwent pterygium excision with limbal-conjunctival autograft transplantation (LCAT).METHODS:Eighty-eight eyes of 88 patients with primary pterygium were included. Pterygia were graded preoperatively from type 1 to type 3 (type 1 atrophic, type 3 inflamed) according to the inflammatory status. The eyes were preoperatively randomized to receive topical steroid and antibiotic treatment (group 1, 46 eyes) and additional topical bevacizumab (5 mg/mL; group 2, 42 eyes) in the postoperative period. All eyes underwent pterygium excision and LCAT. Medications were tapered and discontinued at one month. Postoperative complications and recurrence rates were recorded.RESULTS: The mean follow-up duration was 29.3±4.2mo (24-52mo) and 28.5±3.4 (24-48mo) in group 1 and 2, respectively (P>0.05). There were no statistically significant differences regarding the age or gender between groups (P>0.05). Also, the difference between groups with respect to pterygium type was not significant. During the follow-up period, recurrence developed in 2 eyes (4.3%) in group 1, whereas in one eye (2.4%) in group 2. No statistically significant difference between groups was found in recurrence rates (P>0.05). No re-operation for recurrence was necessary during the follow-up period in both groups. CONCLUSION: Topical bevacizumab seems to have no additonal effect on pterygium recurrence after LCAT.

    Reference
    Related
    Cited by
Get Citation

Aylin Karalezli, Cem Kucukerdonmez, Yonca A. Akova, et al. Does topical bevacizumab prevent postoperative recurrence after pterygium surgery with conjunctival autografting?. Int J Ophthalmol, 2014,7(3):512-516

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
Publication History
  • Received:June 07,2013
  • Revised:September 02,2013
  • Adopted:September 02,2013
  • Online: June 24,2014
  • Published: